Diacerein improves left ventricular remodeling and cardiac function by reducing the inflammatory response after myocardial infarction

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Torina, Anali Galluce ^a   Reichert, Karla ^a   Lima, Fany ^a   De Souza Vilarinho, Karlos Alexandre ^a   De Oliveira, Pedro Paulo Martins ^a   Do Carmo, Helison Rafael Pereira ^a   De Carvalho, Daniela Diógenes ^a   Saad, Mário José Abdalla ^a   Sposito, Andrei Carvalho ^a   Petrucci, Orlando ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; DIACEREIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; ANTHRAQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; CASP3 PROTEIN, RAT; RELA PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CARDIOVASCULAR INFLAMMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART VENTRICLE REMODELING; HEART WEIGHT; HISTOPATHOLOGY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RAT; TNF GENE; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HEART LEFT VENTRICLE FUNCTION; PATHOLOGY; WISTAR RAT;

RATTUS;

ANIMALS; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; CASPASE 3; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; TRANSCRIPTION FACTOR RELA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84929485718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121842     Document Type: Article

References (38)

1. Tang XL, Sanganalmath SK, Sato H, Bi Q, Hunt G, Vincent RJ, et al. Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction. PloS one. 2011; 6(9):e25320. doi: 10.1371/journal.pone.0025320 PMID: 21980426
2. Sogaard P, Gotzsche CO, Ravkilde J, Thygesen K. Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction. Circulation. 1993; 87(4):1093-9. PMID: 8462137
3. Valen G. Innate immunity and remodelling. Heart Fail Rev. 2011; 16(1):71-8. doi: 10.1007/s10741-010-9187-1 PMID: 20694832
4. Christia P, Frangogiannis NG. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest. 2013.
5. Moss NC, Stansfield WE, Willis MS, Tang RH, Selzman CH. IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. American journal of physiology Heart and circulatory physiology. 2007; 293(4):H2248-53. PMID: 17675566
6. Lecour S, James RW. When are pro-inflammatory cytokines SAFE in heart failure? European heart journal. 2011; 32(6):680-5. doi: 10.1093/eurheartj/ehq484 PMID: 21303780
7. Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol. 2006; 41(4):580-91. PMID: 16949095
8. Onai Y, Suzuki J, Maejima Y, Haraguchi G, Muto S, Itai A, et al. Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. American journal of physiology Heart and circulatory physiology. 2007; 292(1):H530-8. PMID: 16920808
9. Lecour S, James RW. When are pro-inflammatory cytokines SAFE in heart failure? European heart journal. 2011.
10. Berthonneche C, Sulpice T, Boucher F, Gouraud L, de Leiris J, O'Connor SE, et al. New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. American journal of physiology Heart and circulatory physiology. 2004; 287(1):H340-50. PMID: 15210453
11. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012; 110 (1):159-73. doi: 10.1161/CIRCRESAHA.111.243162 PMID: 22223212
12. Gigant-Huselstein C, Dumas D, Payan E, Muller S, Bensoussan D, Netter P, et al. In vitro study of intracellular IL-1beta production and beta1 integrins expression in stimulated chondrocytes-effect of rhein. Biorheology. 2002; 39(1-2):277-85. PMID: 12454437
13. de Isla NG, Mainard D, Muller S, Stoltz JF. In vitro effects of diacerein on NO production by chondrocytes in response to proinflammatory mediators. Biomed Mater Eng. 2008; 18(1 Suppl):S99-104. PMID: 18334727
14. Pasin JS, Ferreira AP, Saraiva AL, Ratzlaff V, Andrighetto R, Tomazetti J, et al. Diacerein decreases TNF-alpha and IL-1beta levels in peritoneal fluid and prevents Baker's yeast-induced fever in young rats. Inflammation research: official journal of the European Histamine Research Society [et al]. 2010; 59(3):189-96. doi: 10.1007/s00011-009-0085-8 PMID: 19730987
15. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Boucher M, et al. A Novel and Efficient Model of Coronary Artery Ligation and Myocardial Infarction in the Mouse. Circulation Research. 2010; 107(12):1445-53. doi: 10.1161/CIRCRESAHA.110.223925 PMID: 20966393
16. Jatwa R, Kar A. Anti-inflammatory and anti-peroxidative roles of diacerein are possibly mediated through an alteration in thyroid functions in animal model of inflammation. Fundam Clin Pharmacol. 2009; 23(4):465-71. doi: 10.1111/j.1472-8206.2009.00685.x PMID: 19500155
17. Tobar N, Oliveira AG, Guadagnini D, Bagarolli RA, Rocha GZ, Araujo TG, et al. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology. 2011; 152(11):4080-93. doi: 10.1210/en.2011-0249 PMID: 21896669
18. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc. 2008; 3(9):1422-34. doi: 10.1038/nprot.2008.138 PMID: 18772869
19. Stefanon I, Valero-Munoz M, Fernandes AA, Ribeiro RF Jr., Rodriguez C, Miana M, et al. Left and right ventricle late remodeling following myocardial infarction in rats. PloS one. 2013; 8(5):e64986. doi: 10. 1371/journal.pone.0064986 PMID: 23741440
20. Vilarinho KA, de Oliveira PP, Saad MJ, Eghtesady P, Filho LM, Vieira RW, et al. Erythropoietin protects the systolic function of neonatal hearts against ischaemia/reperfusion injury. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2013; 43 (1):156-62.
21. Stein AB, Bolli R, Dawn B, Sanganalmath SK, Zhu Y, Wang OL, et al. Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. J Mol Cell Cardiol. 2012; 52(1):228-36. doi: 10.1016/j.yjmcc.2011.11.005 PMID: 22119801
22. Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, et al. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation. 2011; 124(19):2094-105. doi: 10.1161/CIRCULATIONAHA.111.030338 PMID: 21986284
23. Kass DA, Beyar R, Lankford E, Heard M, Maughan WL, Sagawa K. Influence of contractile state on curvilinearity of in situ end-systolic pressure-volume relations. Circulation. 1989; 79(1):167-78. PMID: 2910541
24. Ishikawa K, Chemaly ER, Tilemann L, Fish K, Ladage D, Aguero J, et al. Assessing left ventricular systolic dysfunction after myocardial infarction: are ejection fraction and dP/dt(max) complementary or redundant? Am J Physiol Heart Circ Physiol. 2012; 302(7):H1423-8. doi: 10.1152/ajpheart.01211.2011 PMID: 22307667
25. Routledge FS, Campbell TS, McFetridge-Durdle JA, Bacon SL. Improvements in heart rate variability with exercise therapy. Canadian Journal of Cardiology. 2010; 26(6):303-12. PMID: 20548976
26. Zhou W, Benharash P, Ho J, Ko Y, Patel NA, Mahajan A. Left ventricular twist and untwist rate provide reliable measures of ventricular function in myocardial ischemia and a wide range of hemodynamic states. Physiological reports. 2013; 1(5):e00110. doi: 10.1002/phy2.110 PMID: 24303181
27. Wallace AG, Skinner NS Jr., Mitchell JH. Hemodynamic determinants of the maximal rate of rise of left ventricular pressure. Am J Physiol. 1963; 205:30-6. PMID: 13998539
28. Bolognesi R, Tsialtas D, Zeppellini R, Barilli AL, Cucchini F, Manca C. Early and subtle abnormalities of left ventricular function in clinically stable coronary artery disease patients with normal ejection fraction. Journal of Cardiac Failure. 2004; 10(4):304-9. PMID: 15309696
29. Christia P, Bujak M, Gonzalez-Quesada C, Chen W, Dobaczewski M, Reddy A, et al. Systematic characterization of myocardial inflammation, repair, and remodeling in a mouse model of reperfused myocardial infarction. J Histochem Cytochem. 2013; 61(8):555-70. doi: 10.1369/0022155413493912 PMID: 23714783
30. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009; 119(10):1386-97. doi: 10.1161/CIRCULATIONAHA.108.802918 PMID: 19255345
31. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte NF-kappaB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res. 2011; 89(1):129-38. doi: 10.1093/cvr/cvq274 PMID: 20797985
32. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008; 132(3):344-62. doi: 10. 1016/j.cell.2008.01.020 PMID: 18267068
33. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? Journal of Molecular and Cellular Cardiology. 2009; 47(1):32-40. doi: 10.1016/j.yjmcc.2009.03.019 PMID: 19344728
34. Kleinbongard P, Schulz R, Heusch G. TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Failure Reviews. 2011; 16(1):49-69. doi: 10.1007/s10741-010-9180-8 PMID: 20571888
35. Kumar R, Yong QC, Thomas CM. Do multiple nuclear factor kappa B activation mechanisms explain its varied effects in the heart? Ochsner J. 2013; 13(1):157-65. PMID: 23532211
36. Yoshiyama M, Omura T, Takeuchi K, Kim S, Shimada K, Yamagishi H, et al. Angiotensin blockade inhibits increased JNKs, AP-1 and NF-kappa B DNA-binding activities in myocardial infarcted rats. J Mol Cell Cardiol. 2001; 33(4):799-810. PMID: 11273732
37. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NFkappaB. Circ Res. 2011; 108(9):1122-32. doi: 10.1161/CIRCRESAHA.110.226928 PMID: 21527742
38. Gao Y, Chen X, Fang L, Liu F, Cai R, Peng C, et al. Rhein exerts pro-and anti-inflammatory actions by targeting IKKbeta inhibition in LPS-activated macrophages. Free radical biology & medicine. 2014; 72:104-12.